Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura: A phase II, multicenter non-inferiority single-arm study
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms CAPLAVIE
- 24 Jan 2024 Status changed from recruiting to discontinued.
- 05 Jan 2021 New trial record